Nomination Committee for Elicera therapeutics appointed
Gothenburg, October 31, 2023 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on CAR T-cells and oncolytic viruses armed with the company’s commercially available iTANK-platform, announces that representatives of the largest owners have appointed the nomination committee ahead of the Annual General Meeting 2024.
On May 10, the Annual General Meeting established rules to guide the work of the Nomination Committee. The three largest owners on September 30, 2023, were Magnus Essand, Di Yu and Jamal El-Mosleh, who together control 47.1% of the votes, and will be the election committee with Magnus Essand as chairman.
Shareholders who have comments and suggestions are asked to contact the Chairman of the Nomination Committee, Magnus Essand with email [email protected]
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
[email protected]
Certified Advisor
Erik Penser Bank
The information was submitted for publication distributed through the contact person below at 08;10 CET on October 31, 2023.
About the iTANK platform
The iTANK- (immunoTherapies Activated with NAP for efficient Killing) platform is the company's own fully developed commercially available technology platform for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: tumor antigen heterogeneity and a hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating protein (NAP) from the bacterium Helicobacter pylori. Upon activation, NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of the CAR T-cell in addition to activating a parallel immune response via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK-platform is used to enhance the company's own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. More information about iTANK-platform is available here: https://www.elicera.com/technology
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immuno-oncology treatments based on enhanced oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. In addition, Elicera has developed a technology platform called iTANK that can be used to optimize all CAR T-cells in development and activate killer T-cells against cancer. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. For more information, please visit www.elicera.com
